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Background: Anti-glomerular basement membrane (GBM) disease is a well-known antibody-induced autoimmune
disease. A few patients have glomerular C1q deposition, but it is usually absent on renal histopathology. The role of
C1q deposition in kidney injury is unclear. Recently, anti-C1q antibodies are demonstrated to be pathogenic in the
target organ damage of many autoimmune diseases, by facilitating C1q deposition and enhancing complement
activation via classical pathway. In the current study, we investigated the associations between anti-C1q antibodies
in sera and C1q deposition in kidney of patients with anti-GBM disease.
Results: It was shown that the severity of kidney injury was comparable between patients with and without C1q
deposition, including the prevalence of oliguria/auria, the median percentage of crescents in glomeruli and the
mean concentration of serum creatinine. Serum anti-C1q antibodies were detected in 15/25 (60%) patients with a
low titer. The prevalence of C1q deposition in kidney was comparable between patients with and without serum
anti-C1q antibodies (26.7% vs. 30.0%, p > 0.05). No association was found between anti-C1q antibodies and the
severity of kidney injury.
Conclusions: The classical pathway of complement may not play a pathogenic role in the kidney injury of human
anti-GBM disease. Anti-C1q antibodies could be detected in more than half of patients, which need further
investigations.
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Anti-glomerular basement membrane (GBM) disease is
a rare but severe autoimmune disorder which is clinic-
ally characterized by rapidly progressive glomeruloneph-
ritis with or without pulmonary hemorrhage. Anti-GBM
antibodies have been proven to be pathogenic in the dis-
ease initiation [1,2]. The target autoantigen is on the
non-collagenous domain of α3 chain of type IV collagen
on GBM [α3(IV)NC1] [3]. On renal biopsy, linear depos-
ition of anti-GBM IgG is shown along the glomerular
capillary wall, which is always accompanied by linear or
granular deposition of complement 3 (C3) [4]. This* Correspondence: cuizhao@bjmu.edu.cn
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reproduction in any medium, provided the orindicates that the complement system is activated and
may involve in the pathogenesis of the disease.
Animal experiments demonstrated that complement
activation via classical pathway is one of the major
mechanisms for the glomerular injury of anti-GBM dis-
ease [5,6]. The pathway is triggered by the binding of
C1q to anti-GBM IgG coupled with autoantigens, followed
by the activation of C4, C2, C3, C5 and finally the forma-
tion of membrane attack complex, C5b-9. However, other
animal experimental studies demonstrated the protective
role for C1q against the renal inflammation using the ac-
celerated nehprotoxic model [7]. In patients, C1q is sel-
dom shown deposition along GBM on renal biopsy [4].
The circulating and urinary levels of C1q also present little
correlation with the severity of kidney injury [8]. These
make the pathogenic role of classical pathway activation
doubtful in the disease.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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unclear. We speculated it be due to the lack of autoanti-
body against C1q. Anti-C1q antibodies were first found
in the circulation of patients with systemic lupus ery-
thematosus [9] and later identified in many other auto-
immune disorders [10-12]. Anti-GBM antibodies and
anti-C1q antibodies have no cross reaction [13]. Re-
cently, animal studies demonstrated that anti-C1q anti-
bodies are pathogenic in the target organ damage, by
facilitating the C1q deposition in tissues or cell mem-
brane, and then enhancing the complement activation
via classical pathway [14-16].
In the current study, we screened anti-C1q antibodies
in sera of patients with anti-GBM disease. The correl-
ation between the presence of serum anti-C1q antibodies
and C1q deposition on kidney tissues was examined, to-
gether with other clinical and pathological data, with the
aim to find the role of C1q deposition and serum anti-
C1q antibodies in the disease.
Results
Demographic and clinical data of patients
Of the 25 patients, 22 (88%) were male and 3 were female,
with the mean age at 31.8 ± 13.9 years. 12 (48%) patients
presented with pulmonary hemorrhage. The mean level ofFigure 1 C3c, C1q and C4d were detected on frozen renal tissues from
granular deposition along the glomerular capillary wall; b: C1q granular de
capillary wall. d: Negative control.serum creatinine on diagnosis was 991.3 ± 352.0 μmol/L.
The mean level of serum anti-GBM antibodies was 88.6 ±
44.0 U/mL. 2 (8%) patients had positive ANCA, both with
specificity for MPO. The levels of C3 and C4 in circulation
were in normal range of all the patients.
Renal biopsies showed linear staining of IgG, and lin-
ear or granular staining of C3c and C4d along GBM in
all the 25 patients (Figure 1). Crescent formation was
shown in the glomeruli with the range from 29% to
100%. 24 (96%) patients were diagnosed as crescentic
glomerulonephritis (over 50% of the glomeruli had larger
crescents). The percentage of crescents in glomeruli was
positively correlated with the concentration of serum
creatinine at presentation (r = 0.48, P = 0.016).
The clinical and histopathological manifestations of
patients with C1q deposition on GBM
The clinical features of the 7 patients with C1q depos-
ition along GBM were listed in Table 1. Among them, 6
were male and one was female, with a mean age of 43.7 ±
11.8 years. 4 (57.1%) patients presented with lung hemor-
rhage. The mean level of serum creatinine on diagnosis
was 914.3 ± 161.3 μmol/L. On renal biopsy, the mean
percentage of crescent formation in the glomeruli was
83.3 ± 25.5%, with 6 patients diagnosed as crescenticpatients by immunofluorescence (magnification × 400). a: C3c
position along the capillary wall; c: C4d granular deposition along the
Table 1 Comparison of clinical and pathological data of patients with anti-GBM disease with and without glomerular
C1q deposition
With C1q deposition (n = 7) Without C1q deposition (n = 18) p
Age (years) 43.7 ± 11.8 27.2 ± 11.9 0.005
Gender (male/female) 6/1 16/2 1.000
Hydrocarbon exposure 1/7 (14.3%) 2/16 (12.5%) 1.000
Prodromal infection 2/7 (28.6%) 8/18 (44.4%) 0.653
Smoker 3/7 (42.9%) 8/18 (44.4%) 1.000
Hemoptysis 4/7 (57.1%) 8/18 (44.4%) 0.673
Oliguria/anuria 4/7 (57.1%) 10/18 (55.6%) 1.000
Gross hematuria 6/7 (85.7%) 6/18 (33.3%) 0.03
Nephrotic syndrome 2/3 (66.7%) 4/8 (50%) 1.000
Serum creatinine (μmol/L) 914.3 ± 161.3 1021.3 ± 402.9 0.353
Interval from onset (days) 48.6 ± 40.0 48.5 ± 33.3 0.998
Level of anti-GBM antibodies (U/mL) 88.0 ± 49.9 88.8 ± 43.0 0.969
ANCA positive 1/7 (14.3%) 1/18 (5.6%) 0.490
Hemoglobin (g/L) 89.6 ± 25.1 78.2 ± 29.5 0.377
Percentage of crescents in glomeruli (%) 91.0 (77.0-100.0) 100 (88.3-100.0) 0.386
Cellular crescents (%) 75.0 (50.0-100.0) 75.0(24.5-89.5) 0.389
Fibrocellular crescents (%) 25.0 (0–50) 25.0 (10.5-70.0) 0.336
Fibrotic crescents (%) 0 0 0.961
Anti-C1q antibody positive 4/7 (57.1%) 11/18 (61.1%) 1.000
Level of anti-C1q antibodies (relative OD value) 0.210 ± 0.05 0.245 ± 0.06 0.301
Renal survival (1 year) 0/7 (0) 2/18 (11.1%) 1.000
Patient survival (1 year) 3/7 (42.9%) 15/18 (83.3%) 0.066
GBM Glomerular basement membrane, ANCA Anti-neutrophil cytoplasmic antibodies.
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of the glomeruli. At the end of one year after treatment,
all the 7 patients progressed to end stage renal disease
(ESRD) and 4 (57.1%) patients died.
The clinical features of patients with C1q deposition
along GBM were compared with those without C1q
deposition. It was shown that the patients with C1q
deposition were older (43.7 ± 11.8 vs. 27.2 ± 11.9 years,
p = 0.005) and presented with higher incidence of gross
hematuria (85.7% vs. 33.3%, p = 0.03). However, the sever-
ity of kidney injury was comparable between patients with
and without C1q deposition. The prevalence of oliguria/
auria was comparable between them (57.1% vs. 55.6%,
p > 0.05). The mean concentration of serum creatinine
was equivalent between groups (914.3 ± 161.3 vs. 1021.3 ±
402.9 μmol/L, p > 0.05). On renal biopsy, the median per-
centage of crescents in glomeruli was also comparable
between patients with and without C1q deposition (91.0
(77.0-100.0) vs. 100(88.3-100.0)%, p > 0.05). No signifi-
cance difference was observed between the two groups
in gender, serum level of anti-GBM antibody, positive
ANCA, lung hemorrhage, or the renal and patient out-
comes (Table 1).The prevalence of anti-C1q antibodies
The cut-off value (relative OD value) of anti-C1q anti-
bodies was 0.174. Sera from 15/25 (60%) patients were
positive of anti-C1q antibodies in the circulation. The
level of these autoantibodies ranged from 0.178 to 0.338,
with a mean level of 0.236 ± 0.055.
The association between the presence of anti-C1q
antibodies and the clinical manifestations of patients
The clinical features of the 15 patients with positive
serum anti-C1q antibodies were listed in Table 2. Of the
15 patients, 13 were male and 2 were female. The aver-
age age on diagnosis was 34.0 ± 16.0 years old. 6 (40%)
patients had hemoptysis. 2 patients were ANCA positive.
The mean level of serum creatinine on diagnosis was
1016.2 ± 340.0 μmol/L. On renal biopsy, the median per-
centage of crescents in glomeruli was 100.0(84.5-100.0)%,
with 14 patients diagnosed as crescentic glomeruloneph-
ritis. At the end of one year follow up, one patient had his
renal function recovered, the other 14 patients progressed
to ESRD, and 5 patients died.
Glomerular C1q deposition was compared between
patients with and without anti-C1q antibodies. Of the 15
Table 2 Comparison of clinical and pathological data of patients with anti-GBM disease with and without serum anti-C1q
antibodies
Anti-C1q antibody positive (n = 15) Anti-C1q antibody negative (n = 10) P
Age (years) 34.0 ± 16.0 28.5 ± 9.8 0.342
Gender (male/female) 13/2 9/1 1.000
Hydrocarbon exposure 2/15 (13.3%) 1/10 (10%) 1.000
Prodromal infection 5/15 (33.3%) 5/10 (50%) 0.678
Smoker 6/15 (40%) 5/10 (50%) 1.000
Hemoptysis 6/15 (40%) 6/10 (60%) 0.428
Oliguria/anuria 8/15 (53.3%) 6/10 (60%) 1.000
Gross hematuria 6/15 (40%) 6/10 (60%) 0.428
Nephrotic syndrome 4/7 (57.1%) 2/4 (50%) 1.000
Serum creatinine (μmol/L) 1016.2 ± 340.0 954.1 ± 384.7 0.675
Interval from onset (days) 50.4 ± 33.4 46.0 ± 36.8 0.766
Level of anti-GBM antibodies (U/mL) 88.2 ± 49.0 89.2 ± 36.9 0.957
ANCA positive 2/15 (13.3%) 0/10 (0) 0.500
Hemoglobin (g/L) 78.2 ± 24.3 86.1 ± 34.3 0.506
Percentage of crescents in glomeruli (%) 100.0 (90.0-100.0) 88.5 (80.8-100.0) 0.210
Cellular crescents (%) 85.5 (24.8-100.0) 75.0 (29.5-83.3) 0.462
Fibrocellular crescents (%) 14.5 (0–50.0) 25.0 (16.8-68.0) 0.360
Fibrotic crescents (%) 0 (0–2.3) 0 0.443
Positive C1q deposit in the kidney 4/15 (26.7%) 3/10 (30%) 1.000
Renal survival (1 year) 1/15 (6.7%) 1/10 (10%) 1.000
Patient survival (1 year) 10/15 (66.7%) 8/10 (80%) 0.659
GBM Glomerular basement membrane, ANCA Anti-neutrophil cytoplasmic antibodies.
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tients had glomerular C1q deposition. Of the 10 patients
without serum anti-C1q antibodies, 3 (30%) patients had
C1q deposition. The prevalence of glomerular C1q de-
position was comparable between patients with and
without anti-C1q antibodies (26.7% vs. 30%, p > 0.05).
The association between the presence of anti-C1q
antibodies and the severity of kidney injury was further
investigated. Of the 15 patients with positive anti-C1q
antibodies, 8 (53.3%) patients had oliguria/auria. Of the
10 patients without anti-C1q antibodies, 6 (60%) patients
had oliguria/auria. The prevalence of oliguria/auria was
comparable between them (p > 0.05). Similarly, the mean
concentration of serum creatinine was equivalent between
patients with and without anti-C1q antibodies (1016.2 ±
340.0 vs. 954.1 ± 384.7 μmol/L, p > 0.05). On renal biopsy,
the median percentage of crescents in glomeruli was also
comparable between groups (100.0(90.0-100.0) vs. 88.5
(80.8-100.0)%, p > 0.05). There was no significant differ-
ence between the two groups in gender, age, hemoptysis,
anti-GBM antibody levels, ANCA prevalence, or the renal
and patient outcomes (p > 0.05) (Table 2).
The levels of anti-C1q antibodies were all in the low
range. No significant association was found between thelevel of anti-C1q antibodies and the clinical or patho-
logical features (p > 0.05).
Discussion
In the present study, 25 patients were investigated with
renal biopsy-proven anti-GBM disease. They all had lin-
ear IgG deposition accompanied by C3 along GBM on
the kidney tissue. This provides evidence that the com-
plement system was activated in the glomeruli. In the
current study, we also demonstrated the staining of C4d
along GBM in all patients. This indicates the activation
of classical pathway. However, on renal biopsy, C1q de-
position is seldom shown in patients [4]. This makes the
role of classical complement activation controversial in
the kidney injury of anti-GBM disease.
In nephrotoxic nephritis (NTN) animal models, the
role of complement activation via classical pathway has
been studied using the C1q or C3 deficient mice [5-7].
In C1q knockout mice, C3 deposition caused by the in-
duction of heterologous anti-GBM antibodies is attenu-
ated, in comparison with the wild type mice [5,6]. This
indicates a pathogenic role in the mechanism of glom-
erular damage. However, in other studies, a protective
role for C1q against renal inflammation is revealed [7].
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phases, the heterologous phase and the autologous phase,
in the development of kidney injure in this model. The
classical pathway of complement activation may exhibit
different roles in different phases [17]. Another explan-
ation may be the difference between the immune complex
mediated glomerulonephritis in animal models and the
antibody dependent cell cytotoxicity mechanism in human
patients. Thus the mouse models are not reflecting human
anti-GBM disease exactly and are of limited value.
In the current study, we analyzed the clinical and
pathological data and outcomes of the patients with
anti-GBM disease and compared the patients with and
without glomerular C1q deposition in kidney. No associ-
ation was identified between glomerular C1q deposition
and the severity of renal injury or the outcomes of pa-
tients. Neither the percentage of crescent in glomeruli
nor the level of serum creatinine was correlated with
glomerular C1q deposition. These findings indicate that
the classical complement activation may not play a
major pathogenic role in the mechanism of glomerular
damage in human anti-GBM disease. It is consistent
with our previous study, in which we detected the level
of circulating and urinary C1q and found little correl-
ation with the severity of kidney injury [8]. The present
study is limited due to the small sample size. The identi-
fication from multiple centers is needed in the future.
Both the classical and lectin pathways go through the
activation of C4. C4d deposition was demonstrated on
GBM in the glomeruli of our patients. The level of circu-
lating and urinary mannose-binding lectin (MBL) was
detected in our previous study, which had little correl-
ation with the severity of kidney injury [8]. Recently, we
examined the MBL in the kidneys of our patients and
found that MBL deposited diffusively on the GBM and
mesangial area and did not co-localize with C5b-9. How-
ever, the C1q deposit was stained in a linear pattern on
GBM and co-localized well with C5b-9. These findings
indicate that the complement cascade is activated
through the classical pathway, whereas it does not show
a direct pathogenic role to the kidney injury in human
anti-GBM disease.
Animal studies using C4 knockout mice, which lack a
functional classical and lectin pathway, provided strong
evidence for the involvement of alternative pathway in
the complement activation and development of anti-
GBM disease [5,6]. After the induction of heterogeneous
anti-GBM antibodies, C4−/− mice developed albuminuria
similar to that observed in wild type mice. We specu-
lated that both the classical pathway and alternative
pathway participate in the complement activation in hu-
man anti-GBM disease. The alternative pathway may play
more pathogenic role in the kidney injury. The comple-
ment might be activated firstly via the classical pathwayand generate the inflammatory molecules, such as C3a,
C5a and C5b-9, which may be further amplified by the al-
ternative pathway and be crucial in the effector phase of
kidney injury [18-20]. These need further investigations.
The reasons for the absence of C1q deposition in rou-
tine direct immunofluorescence on renal biopsy are un-
clear. Anti-C1q antibodies have been demonstrated to
facilitate the deposition of C1q in target organ and on
cell surface [14,15]. In patients with lupus nephritis, the
serum anti-C1q antibody levels are much higher in pa-
tients with C1q deposition in the kidney than those
without C1q deposit [21]. Coremans et al. have also
detected positive anti-C1q antibodies in less than 50% of
patients with anti-GBM disease [13]. In the present
study, we found 60% of patients having anti-C1q anti-
bodies, whereas the deposition of C1q in glomeruli was
not more frequently shown in the kidney. There may be
two reasons for it. Firstly, the circulating anti-C1q anti-
bodies were mostly in a lower level, which makes them
less effective in facilitating the deposit of C1q. In SLE,
the patients with lupus nephritis present much higher ti-
ters of anti-C1q antibodies than those without kidney in-
jury. The higher titer of anti-C1q antibodies is also an
important predictor for the renal flares [22,23]. Although
we did detect the presentation of anti-C1q antibodies in
the patients with anti-GBM disease, they were all in a
lower level as they were in other autoimmune disease
[12]. The lower titers may prevent the role of anti-C1q
antibodies. Secondly, anti-C1q antibodies may help the
autologous C1q deposit in healthy mice, but induce
overt renal damage only in the context of glomerular
immune complex disease [14-16]. As an organ-specific
autoimmune disease, circulating immune complex does
not play an important role in the pathogenesis of anti-
GBM disease. The target organs are much prone to be
damaged by the humoral and/or cellular mechanisms lo-
cally. There might be other explanation for the absence
of glomerular C1q deposition. Unlike C3d and C4d, C1q
does not bind covalently to its ligands, which results in
its short half-life time in vivo and easy to be cleared by
macrophages [24].
Conclusions
The classical pathway of complement may not play a
pathogenic role in the development of kidney injury of
human anti-GBM disease. Serum anti-C1q antibodies




Between 1996 and 2008, 25 patients with renal biopsy-
proven anti-GBM disease were hospitalized in Peking
University First Hospital. Seven patients, with anti-GBM
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deposition along GBM by direct immunofluorescence,
were used as study group. The other 18 patients, ran-
domly selected from all the patients in the same period,
who had anti-GBM IgG and C3 deposition along GBM,
but no C1q deposition, were used as control group. Pa-
tients with secondary anti-GBM disease or with other
coexisting renal diseases were excluded.
Clinical and pathological parameters were collected
from medical records at the time of presentation and
during follow up. Sera samples were collected at the day
of renal biopsy before the immunosuppressive treat-
ments and stored at −20°C until use. The research was
in compliance of the Declaration of Helsinki and ap-
proved by the ethics committee of the Peking University
First Hospital. Written informed consent was obtained
from each participant.Detection of anti-GBM antibodies and ANCA
Sera from all patients were screened at presentation before
the initiation of immunosuppressive treatment. Anti-GBM
assays were performed by enzyme-linked immunosorbent
assay (ELISA) using purified bovine α(IV)NC1 as solid
phase antigen (EUROIMMUN, Lübeck, Germany), with
confirmation of antibody specificity by ELISA against re-
combinant human α3(IV)NC1. Anti-neutrophil cytoplas-
mic antibody (ANCA) assays were performed by indirect
immunofluorescence (EUROIMMUN, Lübeck, Germany)
using ethanol-fixed human neutrophils. Antigen-specific
ELISA was performed against purified myeloperoxidase
(MPO) and proteinase 3 (PR3).Renal histopathology
Renal biopsy was performed at the time of diagnosis.
Renal specimens were evaluated using direct immuno-
fluorescence, light and electron microscopy and were
forwarded to two pathologists. Both pathologists exam-
ined the biopsies separately, blinded to each other and
the patients’ data.
For direct immunofluorescence, frozen sections were
examined by a fluorescent microscope (Nikon, Tokyo,
Japan) after staining with fluorescein isothiocyanate-
conjugated antibodies specific for human IgG, IgM, IgA,
C1q, fibrinogen and albumin, and tetramethylrhodamine
isothiocyanate-labeled antibodies for C4d and C3c
(Dako, Copenhagen, Denmark). For light microscopy,
paraffin sections were stained with haematoxylin and
eosin, periodic acid-schiff, periodic acid-silver methena-
mine and Masson’s trichrome. For electron microscopy,
biopsy materials were fixed in glutaraldehyde, postfixed
in osmium tetroxide, dehydrated in graded acetone and
embedded in Epon 812 resin. Ultrathin sections were
stained with uranyl acetate and lead citrate, and examinedby a transmission electron microscope JEM-1230 (JEOL,
Tokyo, Japan).
Detection of anti-C1q antibodies
Detection of anti-C1q antibodies were performed by
ELISA as previously described [25,26]. The positive con-
trol was the serum of one patient with lupus nephritis
identified with positive anti-C1q antibodies and the
negative control were the sera from healthy blood do-
nors. Purified normal human C1q (Sigma, St Louis, MO,
USA) diluted at 5 μg/mL in 0.05 M bicarbonate buffer
(pH 9.6) was coated onto the wells of one-half of a poly-
styrene microtiter plate (Costar, Mankato, MN, USA)
overnight at 4°C. The wells in the other half were coated
with bovine serum albumin (BSA) diluted 5 μg/mL in
0.05 M bicarbonate buffer as antigen-free wells for ex-
clusion of non-specific bindings. The volumes of each
well for all steps were 100 μL. All incubations were car-
ried out at 37°C for 1 hour and the plates were washed
three times between every step with 0.01 M phosphate-
buffered saline containing 0.1% Tween 20 (PBST). The
plates were then blocked for 1 hour at 37°C with 1%
(10 mg/ml) BSA in PBST. Sera were diluted to 1:50 in
PBST/0.5 M NaCl and then added in duplicate to both
antigen-coated and antigen-free wells. Each plate
contained a blank, negative and positive control. The
wells were then incubated with 1:5000 diluted alkaline
phosphatase-conjugated goat anti-human IgG (Fc spe-
cific, Sigma, St Louis, MO, USA). The results were
recorded as the net optical absorbance (average value of
antigen-coated wells minus average value of antigen-free
wells) at 405 nm (Bio-Rad 550, Tokyo, Japan). The ab-
sorbance value of positive controls should be around
1.5-2.0 in each assay. To make the results comparable
between assays, the relative values for positive control
and blank control were defined as 1.0 and 0.0, respect-
ively. Autoantibody levels of the tested sera were
expressed as relative values. Samples were considered
positive if they exceeded the mean plus 2 standard devia-
tions from 25 age- and gender-matched healthy blood
donors.
Statistical analysis
Differences of quantitative data were assessed using Stu-
dent’s t test (for normally distributed data: serum cre-
atinine, level of anti-GBM antibodies, hemoglobin and
level of anti-C1q antibodies) or nonparametric test (for
non-normally distributed data: percentage of crescents
in glomeruli, cellular crescents, fibrocellular crescents,
fibrotic crescents). Pearson’s correlation test was used to
measure the correlation between two normally distrib-
uted variables. Spearman’s correlation test was used to
measure the correlation between two non-normally dis-
tributed variables or one normally with one non-normally
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formed using the Cox regression model. All statistical ana-
lyses were two-tailed and P < 0.05 was considered as
significant. Statistical software SPSS 18.0 (SPSS, Chicago,
IL, USA) was employed for statistical analysis.
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